Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BEAM

Beam Therapeutics Inc

Feb 13 • 04:00PM ET

27.92

+0.99 3.68 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK XBI VTI IWM ARKG VB VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-4.43	Insider Own	9.81%	Shs Outstand	101.36M	Perf Week	5.28%
Market Cap	2.83B	Forward P/E	-	EPS next Y	-4.67	Insider Trans	-1.37%	Shs Float	91.52M	Perf Month	-21.15%
Enterprise Value	1.91B	PEG	-	EPS next Q	-1.00	Inst Own	94.28%	Short Float	21.21%	Perf Quarter	27.66%
Income	-414.64M	P/S	50.86	EPS this Y	8.62%	Inst Trans	-3.60%	Short Ratio	10.41	Perf Half Y	58.37%
Sales	55.70M	P/B	2.93	EPS next Y	-11.54%	ROA	-33.41%	Short Interest	19.41M	Perf YTD	0.72%
Book/sh	9.53	P/C	2.64	EPS next 5Y	-1.27%	ROE	-47.19%	52W High	36.44 -23.38%	Perf Year	-2.41%
Cash/sh	10.59	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-37.53%	52W Low	13.52 106.43%	Perf 3Y	-35.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	60.38%	Volatility	6.03% 7.32%	Perf 5Y	-73.41%
Dividend TTM	-	EV/Sales	34.28	EPS Y/Y TTM	-157.71%	Oper. Margin	-837.12%	ATR (14)	2.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.02	Sales Y/Y TTM	-84.07%	Profit Margin	-744.41%	RSI (14)	48.97	Recom	1.28
Dividend Gr. 3/5Y	- -	Current Ratio	6.02	EPS Q/Q	6.31%	SMA20	-3.02%	Beta	2.12	Target Price	46.53
Payout	-	Debt/Eq	0.16	Sales Q/Q	-32.03%	SMA50	-1.97%	Rel Volume	0.98	Prev Close	26.93
Employees	483	LT Debt/Eq	0.14	Earnings	Nov 04 BMO	SMA200	23.66%	Avg Volume	1.86M	Price	27.92
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.99% -14.46%	Trades		Volume	1,829,630	Change	3.68%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117

Show Previous Ratings

Jan-29-26 07:17AM	Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) (Insider Monkey)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 04:15PM	Beam Soars 22% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily) +22.29%
03:37PM	Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference (MarketBeat)
01:39PM	Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? (Benzinga)
12:54PM	Loading…
12:54PM	Beam Soars Nearly 30% As FDA Signs Off On Its Ambitious Gene-Editing Plan (Investor's Business Daily)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition (GlobeNewswire)
Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.59%
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:46PM	Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene (Insider Monkey)
07:33AM	Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
06:50AM	Loading…
Dec-22-25 06:50AM	BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy (Insider Monkey) +5.08%
Dec-18-25 04:01PM	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-06-25 08:00AM	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks) +8.12%
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.82%
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga)
07:00AM	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-25 08:16PM	Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Loading…
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
Nov-04-25 03:37PM	Cathie Wood unloads $7.69 million in top AI stock (TheStreet) -6.23%
03:37PM	Cathie Wood sells another $7.69 million in leading AI stock (TheStreet)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
09:00AM	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks) +5.08%
01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
Oct-30-25 12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks) -6.28%
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:55AM	Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-25 09:55AM	Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +17.86%
09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans John M.	CEO	Jan 29 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Option Exercise	0.67	25,000	16,750	1,011,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 29 '26	Sale	29.38	25,000	734,582	986,667	Feb 02 04:05 PM
Evans John M.	CEO	Jan 30 '26	Sale	28.36	25,000	708,946	986,667	Feb 02 04:05 PM
JOHN M EVANS	Officer	Jan 30 '26	Proposed Sale	28.36	25,000	708,948		Jan 30 04:04 PM
JOHN M EVANS	Officer	Jan 29 '26	Proposed Sale	29.38	25,000	734,582		Jan 29 04:01 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 22 '26	Sale	35.00	6,198	216,933	34,813	Jan 26 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 22 '26	Sale	34.00	1,371	46,614	95,667	Jan 26 04:05 PM
CHRISTINE BELLON	Officer	Jan 22 '26	Proposed Sale	34.00	1,371	46,614		Jan 22 04:03 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 20 '26	Sale	30.12	3,034	91,384	41,011	Jan 21 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 15 '26	Sale	34.61	18,629	644,832	97,038	Jan 20 04:05 PM
CHRISTINE BELLON	Officer	Jan 15 '26	Proposed Sale	34.61	18,629	644,831		Jan 15 06:00 PM
Emany Sravan Kumar	Chief Financial Officer	Dec 31 '25	Sale	27.10	6,294	170,567	73,706	Jan 05 04:16 PM
Bellon Christine	Chief Legal Officer	Dec 31 '25	Sale	27.10	1,254	33,983	115,667	Jan 05 04:12 PM
FMR LLC	See Remark 1	Oct 27 '25	Sale	26.68	459	12,246	14	Oct 29 01:13 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '25	Sale	24.53	467	11,456	44,045	Oct 03 04:15 PM
Bellon Christine	Chief Legal Officer	Oct 01 '25	Sale	24.53	373	9,150	116,921	Oct 03 04:10 PM
Evans John M.	CEO	Oct 01 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Sale	24.63	25,000	615,668	986,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 01 '25	Sale	24.51	25,000	612,655	986,667	Oct 03 04:05 PM
JOHN M EVANS	Officer	Oct 02 '25	Proposed Sale	24.63	25,000	615,668		Oct 02 04:23 PM
JOHN M EVANS	Officer	Oct 01 '25	Proposed Sale	24.51	25,000	612,655		Oct 01 04:12 PM
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM

Open in Screener

RXRX

Recursion Pharmaceuticals Inc

Feb 13 • 04:00PM ET

3.49

-0.09 -2.51 %

Healthcare • Biotechnology • USA • NASD

RXRX Recursion Pharmaceuticals Inc daily Stock Chart

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK VTI XBI ARKG VB IWM VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.46%	Shs Outstand	485.21M	Perf Week	-12.31%
Market Cap	1.82B	Forward P/E	-	EPS next Y	-1.14	Insider Trans	-1.86%	Shs Float	434.79M	Perf Month	-28.04%
Enterprise Value	1.24B	PEG	-	EPS next Q	-0.30	Inst Own	53.10%	Short Float	38.08%	Perf Quarter	-24.95%
Income	-715.54M	P/S	41.57	EPS this Y	7.30%	Inst Trans	1.40%	Short Ratio	7.32	Perf Half Y	-38.12%
Sales	43.69M	P/B	1.64	EPS next Y	27.38%	ROA	-67.31%	Short Interest	165.55M	Perf YTD	-14.67%
Book/sh	2.13	P/C	2.74	EPS next 5Y	17.77%	ROE	-91.06%	52W High	12.36 -71.76%	Perf Year	-58.94%
Cash/sh	1.27	P/FCF	-	EPS past 3/5Y	-15.58% -35.28%	ROIC	-64.53%	52W Low	3.49 0.00%	Perf 3Y	-56.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	79.47% 90.93%	Gross Margin	-160.40%	Volatility	6.45% 6.67%	Perf 5Y	-
Dividend TTM	-	EV/Sales	28.29	EPS Y/Y TTM	-18.46%	Oper. Margin	-1656.17%	ATR (14)	0.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.60	Sales Y/Y TTM	-32.98%	Profit Margin	-1637.81%	RSI (14)	33.44	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	-7.02%	SMA20	-16.78%	Beta	0.97	Target Price	7.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-80.16%	SMA50	-20.42%	Rel Volume	0.70	Prev Close	3.58
Employees	-	LT Debt/Eq	0.06	Earnings	Nov 05 BMO	SMA200	-29.04%	Avg Volume	22.63M	Price	3.49
IPO	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.53% -70.60%	Trades		Volume	15,943,542	Change	-2.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight	$11
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Feb-12-26 10:00AM	2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off (24/7 Wall St.)
07:59AM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
Feb-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-04-26 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -8.72%
Jan-29-26 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
09:25AM	Loading…
09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
06:15AM	Forget 2025: These 2 Growth Stocks Could Soar in 2026 (Motley Fool)
Jan-28-26 09:21PM	Can This Beaten-Down AI Stock Bounce Back in 2026? (Motley Fool)
Jan-24-26 03:35AM	Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? (Insider Monkey)
Jan-23-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-20-26 10:14AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) -5.78%
Jan-18-26 12:30PM	JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects (Insider Monkey)
Jan-16-26 05:05PM	2 AI Stocks to Buy in 2026, and 1 to Avoid (Motley Fool) -5.78%
Jan-15-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-08-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:20PM	Loading…
Jan-07-26 08:20PM	Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates (Insider Monkey) +6.81%
Jan-06-26 07:59AM	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
09:10AM	JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline (Insider Monkey)
Jan-01-26 07:45AM	Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. (Motley Fool)
Dec-30-25 11:49PM	Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
Dec-29-25 11:42AM	Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP (Insider Monkey)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Dec-28-25 12:46PM	Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform (Insider Monkey)
Dec-24-25 09:00AM	Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? (Barchart)
Dec-21-25 07:40AM	Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? (Insider Monkey)
Dec-19-25 07:33AM	Cathie Wood Keeps Dumping Tesla Stock -- Here is Why (GuruFocus.com)
Dec-18-25 05:24AM	Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet (Insider Monkey) -5.13%
Dec-17-25 05:27PM	Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday (Motley Fool) +11.43%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
05:30PM	Loading…
Dec-08-25 05:30PM	Why Recursion Pharamaceuticals Topped the Market Today (Motley Fool)
07:30AM	Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks (GlobeNewswire)
12:32AM	Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" (Insider Monkey)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:04PM	Lightning Round: Recursion Pharmaceuticals and NuScale Power (CNBC TV) +5.58%
06:05AM	10 AI Stocks Worth Buying Right Now (Motley Fool)
Dec-01-25 08:30AM	Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 (GlobeNewswire) -5.83%
Nov-28-25 06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-24-25 08:53AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Nov-22-25 10:11AM	Recursion (RXRX) Jumps 8% on Bargain-Hunting (Insider Monkey)
Nov-21-25 05:02AM	Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? (Insider Monkey) +8.31%
Nov-19-25 08:13AM	Is Recursion Pharmaceuticals a Meme Stock? (Motley Fool)
Nov-12-25 09:45AM	Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock (Motley Fool)
Nov-06-25 09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks) -6.85%
Nov-05-25 07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:34AM	Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:28AM	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth (GlobeNewswire)
Nov-04-25 08:45AM	3 Things Investors Need to Know About Recursion Pharmaceuticals (Motley Fool) -8.09%
08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-31-25 06:15AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Oct-29-25 10:00AM	Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks) -6.19%
08:00AM	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th (GlobeNewswire)
Oct-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.89%
08:56AM	Jim Cramer on Recursion Pharmaceuticals: "Now, It's a Meme Stock" (Insider Monkey)
Oct-21-25 12:56PM	Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings (Insider Monkey) -8.53%
10:00AM	Up 25% in 1 Month, Is This Stock a Buy? (Motley Fool)
Oct-19-25 04:00AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Oct-16-25 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -6.33% -7.86%
10:30AM	Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event (Insider Monkey)
09:31AM	Is Recursion Pharmaceuticals a Millionaire Maker? (Motley Fool)
Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 05:00AM	Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference (Insider Monkey)
Oct-08-25 11:22AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) +16.44%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
Oct-07-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.42%
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-30-25 02:49PM	Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) (Insider Monkey)
Sep-29-25 09:02AM	Nvidia Has Invested in These 6 Companies. Should You Follow Suit? (Motley Fool)
01:22AM	Jim Cramer on Recursion: "I Need to See a Proof of Concept Here" (Insider Monkey)
Sep-28-25 10:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
09:32AM	The Biotech Stock That's Too Risky for Most Investors (Motley Fool)
07:00AM	Nvidias $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidias cash being recycled? (Fortune)
Sep-27-25 06:45AM	10 Hidden-Gem AI Stocks to Buy Right Now (Motley Fool)
Sep-26-25 04:42AM	Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now (Motley Fool)
Sep-25-25 09:15AM	Looking for the Next Big Pop? Heres Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce (Barchart) -5.12%
Sep-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
Sep-21-25 09:26AM	Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances (Insider Monkey)
Sep-15-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:17AM	Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 (Insider Monkey)
04:44AM	Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. (Motley Fool)
Sep-03-25 06:00AM	When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts (Motley Fool)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:45AM	3 AI Stocks Disrupting Trillion-Dollar Industries (Motley Fool)
Aug-29-25 08:30AM	If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-28-25 05:05AM	Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:45AM	1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell (Motley Fool)
Aug-24-25 12:53AM	Needham Maintains Buy Rating on Recursion (RXRX) (Insider Monkey)
Aug-23-25 04:00AM	The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode (Motley Fool)
Aug-22-25 05:53PM	Why Recursion Pharmaceuticals Stock Caught a Cold This Week (Motley Fool)
Aug-21-25 10:45AM	Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-17-25 06:16PM	Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid (Insider Monkey)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.36%
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Director	Feb 04 '26	Sale	4.12	40,000	164,800	913,839	Feb 06 05:53 PM
Borgeson Blake	Director	Feb 03 '26	Sale	4.20	220,000	924,000	6,429,863	Feb 06 05:53 PM
Gibson Christopher	Director	Feb 04 '26	Proposed Sale	4.12	40,000	164,800		Feb 04 09:50 AM
Borgeson Blake	Director	Feb 03 '26	Proposed Sale	4.20	220,000	924,000		Feb 03 11:26 AM
Gibson Christopher	Director	Jan 20 '26	Sale	4.47	40,000	178,800	913,839	Jan 22 07:34 PM
Gibson Christopher	Director	Jan 20 '26	Proposed Sale	4.47	40,000	178,800		Jan 20 11:26 AM
Borgeson Blake	Director	Jan 06 '26	Sale	4.36	220,000	959,200	6,649,863	Jan 08 05:01 PM
Gibson Christopher	Director	Jan 05 '26	Sale	4.25	40,000	170,000	933,839	Jan 07 05:04 PM
Borgeson Blake	Director	Jan 06 '26	Proposed Sale	4.36	220,000	959,200		Jan 06 09:40 AM
Gibson Christopher	Director	Jan 05 '26	Proposed Sale	4.25	40,000	170,000		Jan 05 11:07 AM
Taylor Ben R	Chief Financial Officer	Dec 29 '25	Sale	4.18	21,383	89,381	761,550	Dec 30 07:35 PM
Khan Najat	Chief R&D Commercial Officer	Dec 22 '25	Sale	4.41	124,403	548,592	611,135	Dec 29 05:24 PM
Taylor Ben R	Officer	Dec 29 '25	Proposed Sale	4.18	21,383	89,381		Dec 29 09:41 AM
Najat Khan	Officer	Dec 22 '25	Proposed Sale	4.41	124,403	548,588		Dec 22 12:20 PM
Gibson Christopher	Chief Executive Officer	Dec 19 '25	Sale	4.50	40,000	180,000	913,839	Dec 19 05:04 PM
Gibson Christopher	Officer	Dec 19 '25	Proposed Sale	4.50	40,000	180,000		Dec 19 09:52 AM
Gibson Christopher	Chief Executive Officer	Dec 04 '25	Sale	4.63	40,000	185,200	933,839	Dec 05 07:20 PM
Borgeson Blake	Director	Dec 02 '25	Sale	4.37	220,000	961,400	6,869,863	Dec 04 04:51 PM
Gibson Christopher	Officer	Dec 04 '25	Proposed Sale	4.63	40,000	185,200		Dec 04 10:01 AM
Borgeson Blake	Director	Dec 02 '25	Proposed Sale	4.37	220,000	961,400		Dec 02 12:15 PM
Gibson Christopher	Chief Executive Officer	Nov 19 '25	Sale	4.16	40,000	166,400	913,839	Nov 19 07:37 PM
Gibson Christopher	Officer	Nov 19 '25	Proposed Sale	4.16	40,000	166,400		Nov 19 10:17 AM
Gibson Christopher	Chief Executive Officer	Nov 04 '25	Sale	5.21	40,000	208,400	974,229	Nov 06 04:23 PM
Gibson Christopher	Officer	Nov 04 '25	Proposed Sale	5.21	40,000	208,400		Nov 04 09:51 AM
Gibson Christopher	Chief Executive Officer	Oct 23 '25	Sale	5.70	100,000	570,000	954,229	Oct 24 06:49 PM
Gibson Christopher	Officer	Oct 23 '25	Proposed Sale	5.70	100,000	570,000		Oct 23 10:37 AM
Gibson Christopher	Chief Executive Officer	Oct 10 '25	Sale	6.04	100,000	604,000	974,229	Oct 10 06:03 PM
Gibson Christopher	Officer	Oct 10 '25	Proposed Sale	6.04	100,000	604,000		Oct 10 10:24 AM
Gibson Christopher	Chief Executive Officer	Sep 25 '25	Sale	4.76	100,000	476,000	954,229	Sep 26 06:32 PM
Gibson Christopher	Officer	Sep 25 '25	Proposed Sale	4.76	100,000	476,000		Sep 25 09:49 AM
Gibson Christopher	Chief Executive Officer	Sep 10 '25	Sale	4.71	100,000	471,000	974,229	Sep 12 04:24 PM
Gibson Christopher	Officer	Sep 10 '25	Proposed Sale	4.71	100,000	471,000		Sep 10 11:10 AM
Gibson Christopher	Chief Executive Officer	Aug 26 '25	Sale	4.84	100,000	484,000	954,229	Aug 28 08:00 PM
Gibson Christopher	Officer	Aug 26 '25	Proposed Sale	4.84	100,000	484,000		Aug 26 10:03 AM
Khan Najat	Chief R&D Commercial Officer	Aug 18 '25	Sale	5.52	36,599	202,173	668,197	Aug 19 06:22 PM
Khan Najat	Officer	Aug 18 '25	Proposed Sale	5.52	36,599	202,169		Aug 18 03:18 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	500,300	2,641,584	1,004,619	Aug 13 09:03 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	117,875	622,380	0	Aug 13 09:03 PM
Gibson Christopher	Officer	Aug 11 '25	Proposed Sale	5.28	617,875	3,262,380		Aug 11 03:31 PM
Gibson Christopher	Chief Executive Officer	Mar 27 '25	Sale	6.04	138,574	836,987	1,117,450	Mar 28 04:52 PM
Gibson Christopher	Officer	Mar 27 '25	Proposed Sale	6.04	138,574	836,987		Mar 27 12:02 PM
Gibson Christopher	Chief Executive Officer	Mar 05 '25	Sale	6.58	20,000	131,600	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '25	Sale	6.37	20,000	127,400	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Officer	Mar 06 '25	Proposed Sale	6.37	20,000	127,400		Mar 06 11:55 AM
Gibson Christopher	Officer	Mar 05 '25	Proposed Sale	6.58	20,000	131,600		Mar 05 10:13 AM

BEAM

Beam Therapeutics Inc

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience